靶向α治疗复发性高级别胶质瘤:[²²⁵Ac]-PSMA诊疗新策略
本研究评估了[²²⁵Ac]-PSMA系统性靶向α治疗复发性高级别胶质瘤的可行性、安全性和初步疗效。四例复发性高级别胶质瘤患者接受每周期100 kBq/kg的[²²⁵Ac]-PSMA治疗,所有患者最终均出现疾病进展,但一例预设PSMA高摄取指标病灶消退、另一例保持稳定,未观察到≥3级不良事件或治疗相关死亡。
要点
- 四例复发性高级别胶质瘤患者接受[²²⁵Ac]-PSMA治疗,每周期剂量100 kBq/kg。
- 所有患者最终出现疾病进展,但一例指标病灶消退、一例保持稳定。
- 未观察到≥3级不良事件或治疗相关死亡,低级别毒性主要为轻度口干。
核心结论
- 系统性[²²⁵Ac]-PSMA治疗在复发性高级别胶质瘤中可行且耐受性良好,并显示初步的疾病控制证据。
研究设计与样本
- 四例组织学确诊的复发性高级别胶质瘤患者接受[²²⁵Ac]-PSMA治疗,每周期剂量100 kBq/kg,治疗周期计划间隔8-12周。
- 队列包括三例胶质母细胞瘤和一例WHO III级高级别弥漫性胶质瘤,诊断依据诊断时适用的WHO分类。
- 基线和随访评估采用[⁶⁸Ga]-PSMA PET/MRI或PET/CT视觉及半定量参数,并结合增强MRI,全程监测临床状态和血液学参数。
主要发现
- 所有患者最终在治疗后出现疾病进展,但一例预设PSMA高摄取指标病灶消退,另一例保持稳定。
- 未观察到归因于[²²⁵Ac]-PSMA的≥3级不良事件或治疗相关死亡。
- 低级别毒性有限,主要为轻度口干。
临床怎么用
- 对于复发性高级别胶质瘤,[²²⁵Ac]-PSMA靶向α治疗可作为探索性诊疗选择,需在严格监测下进行。
- 治疗前应通过[⁶⁸Ga]-PSMA PET评估病灶PSMA摄取以筛选潜在获益患者。
局限性
- 样本量仅四例,结论的普遍性有限。
- 所有患者最终均出现疾病进展,初步疗效证据尚需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the feasibility, safety, and preliminary efficacy of systemic targeted alpha therapy with [²²⁵Ac]-PSMA in patients with recurrent high-grade glioma (HGG). Glioblastoma multiforme (GBM) and HGGs are highly aggressive primary brain tumors with limited treatment options at recurrence. Expression of prostate-specific membrane antigen (PSMA) in the neovasculature of GBM provides a promising target for radioligand therapy using alpha emitters such as Actinium-225. METHODS: Four patients with histologically confirmed recurrent HGG received [²²⁵Ac]-PSMA therapy at a dose of 100 kBq/kg per cycle. Diagnoses were established according to the WHO classification available at the time of diagnosis. The cohort included three patients with GBM and one patient with a high-grade diffuse glial tumor, WHO grade III. Treatment cycles were intended at 8-12-week intervals. Baseline and follow-up assessments were performed visually and then semi-quantitave parameters were described on [⁶⁸Ga]-PSMA PET/MRI or PET/CT images also using contrast-enhanced MRI. Clinical status and hematologic parameters were monitored throughout therapy and follow-up. RESULTS: While every patient ultimately developed progressive disease following treatment, the predefined PSMA-avid index lesion regressed in one patient and remained stable in another. No grade ≥ 3 adverse events attributable to [²²⁵Ac]-PSMA or treatment-related mortality were observed. Low-grade toxicity was limited and mainly consisted of mild xerostomia. CONCLUSION: Systemic [²²⁵Ac]-PSMA therapy appeared feasible and well tolerated, showing preliminary evidence of disease control in recurrent HGGs.
引用
- Sayman HB, Aras O, Hekim MV, et al. Targeted alpha therapy for recurrent high-grade glioma with [²²⁵Ac]-PSMA: a new theranostic approach. Eur J Nucl Med Mol Imaging. 2026. PMID: 42764297. doi:10.1007/s00259-026-08194-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。